These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22170530)

  • 1. Salt and aldosterone do not get along with each other: implication of mineralocorticoid receptors in the profibrotic action of aldosterone.
    Armanini D; Calò L; Fiore C
    Kidney Int; 2012 Jan; 81(1):118. PubMed ID: 22170530
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
    Nagase M; Fujita T
    Nihon Jinzo Gakkai Shi; 2010; 52(2):125-31. PubMed ID: 20415233
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications].
    Bertocchio JP; Jaisser F
    Nephrol Ther; 2011 Jun; 7(3):139-47. PubMed ID: 21144811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salt in the wound.
    Brown NJ
    J Am Soc Nephrol; 2009 Jan; 20(1):5-6. PubMed ID: 19118146
    [No Abstract]   [Full Text] [Related]  

  • 5. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
    Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
    Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor--Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats.
    Kawarazaki H; Ando K; Shibata S; Muraoka K; Fujita M; Kawarasaki C; Fujita T
    J Hypertens; 2012 Oct; 30(10):1977-85. PubMed ID: 22914542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.
    Bertocchio JP; Warnock DG; Jaisser F
    Kidney Int; 2011 May; 79(10):1051-60. PubMed ID: 21412221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kidney diseases and mineralocorticoid receptor].
    Nagase M
    Nihon Naika Gakkai Zasshi; 2009 Nov; 98(11):2894-902. PubMed ID: 22462146
    [No Abstract]   [Full Text] [Related]  

  • 9. The nongenomic actions of aldosterone.
    Funder JW
    Endocr Rev; 2005 May; 26(3):313-21. PubMed ID: 15814845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells.
    Boldyreff B; Wehling M
    Nephrol Dial Transplant; 2003 Sep; 18(9):1693-5. PubMed ID: 12937210
    [No Abstract]   [Full Text] [Related]  

  • 11. Direct and Indirect Mineralocorticoid Effects Determine Distal Salt Transport.
    Terker AS; Yarbrough B; Ferdaus MZ; Lazelle RA; Erspamer KJ; Meermeier NP; Park HJ; McCormick JA; Yang CL; Ellison DH
    J Am Soc Nephrol; 2016 Aug; 27(8):2436-45. PubMed ID: 26712527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
    Bauersachs J; Jaisser F; Toto R
    Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mechanisms of neurogenic dystrophies induced by activation and deprivation of the sympathetic nervous system].
    Akimov IuA; Kositsyn NS
    Izv Akad Nauk Ser Biol; 2005; (2):226-31. PubMed ID: 16004286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participation of the mineralocorticoid receptor in cardiac and vascular remodeling.
    Fiebeler A; Haller H
    Nephron Physiol; 2003; 94(3):p47-50. PubMed ID: 12902615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
    Funder JW
    Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone and mineralocorticoid receptors: orphan questions.
    Funder JW
    Kidney Int; 2000 Apr; 57(4):1358-63. PubMed ID: 10760067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone and mineralocorticoid receptors: a personal reflection.
    Funder JW
    Mol Cell Endocrinol; 2012 Mar; 350(2):146-50. PubMed ID: 22155566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent aspects of the action of aldosterone].
    Farman N
    Nephrologie; 1993; 14(4):163-9. PubMed ID: 8232710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms underlying rapid aldosterone effects in the kidney.
    Thomas W; Harvey BJ
    Annu Rev Physiol; 2011; 73():335-57. PubMed ID: 20809792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.